Ab­b­Vie says it has pos­i­tive mid-stage da­ta for Rin­voq in lu­pus, will move to PhI­II

Ab­b­Vie is teas­ing new Phase II da­ta in the most com­mon form of lu­pus — and the phar­ma com­pa­ny says it is good enough to move in­to a piv­otal tri­al.

The drug com­pa­ny shared ini­tial re­sults Thurs­day, say­ing that its JAK block­buster Rin­voq met the pri­ma­ry goals of a Phase II tri­al in sys­temic lu­pus ery­the­mato­sus. The tri­al looked at whether Rin­voq led to a re­duc­tion of at least four points on a scor­ing sys­tem called SLE Dis­ease Ac­tiv­i­ty In­dex 2000 with­out the con­di­tion wors­en­ing over­all or the pa­tient de­vel­op­ing sub­stan­tial dis­ease ac­tiv­i­ty in new or­gans. It al­so re­quired that pa­tients not need more than a 10 mg dai­ly dose of steroid pred­nisone or an equiv­a­lent.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN